Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Inotuzumab Ozogamicin in Indolent Non-Hodgkin Lymphoma
2008-001635-34Phase 2Completed
- Sponsor
- Wyeth
- Start
- Apr 2009
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inotuzumab ozogamicin in non-Hodgkin lymphoma (NHL), sponsored by Wyeth. Primary endpoint: Confirmed overall response rate (ORR). Started Apr 2009; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2008-001635-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001635-34.